AbbVie CEO Pleads For U.S. Tax Reform In Eulogy For Shire Merger
This article was originally published in The Pink Sheet Daily
U.S. tax policy changes intended to curb inversion deals criticized by Gonzalez during conference call announcing breakup of $54 billion AbbVie/Shire merger.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.